The Effect of Polyphenolic Composition BP-C3 on the Efficacy and Hematological Toxicity of Cyclophosphamide in the Chemotherapy of Mice Bearing Soft Tissue Sarcomas Induced by Benzo[a]pyrene

• Published in: Integrative cancer therapies 2019-01, Vol.18, p.1534735419833778-1534735419833778
• Main Authors: Panchenko, Andrey V., Fedoros, Elena I., Pigarev, Sergey E., Maydin, Mikhail A., Gubareva, Ekaterina A., Kireeva, Galina S., Tyndyk, Margarita L., Kuznetsova, Anastasia I., Nekhaeva, Tatyana L., Danilova, Anna B., Baldueva, Irina A., Anisimov, Vladimir N.
• Format: Article
• Language: English
• Subjects: Animals; Antineoplastic Combined Chemotherapy Protocols - pharmacology; Antitumor activity; Benzo(a)pyrene; Benzo(a)pyrene - pharmacology; Chemotherapy; Cyclophosphamide; Cyclophosphamide - adverse effects; Cyclophosphamide - pharmacology; Erythrocytes; Female; Growth inhibition; Hematologic Diseases - chemically induced; Hematology; Lignin; Male; Mice; Polyphenols - pharmacology; Pyrene; Rodents; Sarcoma; Sarcoma - drug therapy; Toxicity
• ISSN: 1534-7354; 1552-695X
• DOI: 10.1177/1534735419833778

This study aimed to evaluate the effect of lignin-derived polyphenolic composition BP-C3 on the efficacy and hematological toxicity of cyclophosphamide (CPA). Male and female Swiss-H derived mice bearing benzo[a]pyrene-induced soft tissue sarcomas were treated with CPA 300 mg/kg, BP-C3 75 mg/kg, or a combination. Tumor growth inhibition in male mice treated with CPA, BP-C3, or a combination of CPA and BP-C3 was significant and corresponded to 78%, 45%, and 82%, respectively, on day 21 after CPA administration on day 0. In female mice, tumor growth inhibition was 58%, −11%, and 35% when treated with CPA, BP-C3, or a combination of CPA and BP-C3, respectively. CPA administration resulted in significant hematological toxicity evidenced by a decreased white blood cell count on day 4 (2.43 ± 1.77 × 109/L in male mice and 1.19 ± 0.71 × 109/L in female mice) and anemia development on day 7 (6.55 ± 1.74 × 1012/L in male mice and 5.89 ± 2.24 × 1012/L in female mice). The red blood cell count measured on day 7 in animals treated with the combination of BP-C3 and CPA constituted 7.12 ± 1.17 × 1012/L and 7.36 ± 2.07 × 1012/L for male and female mice, respectively. The results of our study demonstrate the antitumor activity of BP-C3 in male mice bearing soft tissue sarcomas. Neither the antitumor activity nor the hematological toxicity of CPA were significantly influenced by BP-C3. A less pronounced effect of CPA on RBC count is demonstrated when this agent is given jointly with BP-C3.